Immune dysregulation in cancer patients developing immune-related adverse events

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy

(2018) Ryuma Tokunaga et al.   CANCER TREATMENT REVIEWS

How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis

(2018) Saad A. Khan et al.   LUNG CANCER

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

Tissue-specific regulation of CXCL9/10/11 chemokines in keratinocytes: Implications for oral inflammatory disease

(2017) Alison Marshall et al.   PLoS One

Biomarkers associated with checkpoint inhibitors

(2016) G. Manson et al.   ANNALS OF ONCOLOGY

Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events

(2016) Elisa González-Rodríguez et al.   ONCOLOGIST

Prevalence of Autoimmune Disease Among Patients With Lung Cancer

(2016) Saad A. Khan et al.   JAMA Oncology

Treg-cell depletion promotes chemokine production and accumulation of CXCR3+conventional T cells in intestinal tumors

(2015) Paulina Akeus et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

CXCL13, CCL21, and CXCL12 Expression in Salivary Glands of Patients with Sjogren's Syndrome and MALT Lymphoma: Association with Reactive and Malignant Areas of Lymphoid Organization

(2014) F. Barone et al.   JOURNAL OF IMMUNOLOGY

Selected Cytokines in Patients with Pancreatic Cancer: A Preliminary Report

(2014) Wojciech Błogowski et al.   PLoS One

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2

(2013) D Bedognetti et al.   BRITISH JOURNAL OF CANCER

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma

(2012) T Kantola et al.   BRITISH JOURNAL OF CANCER

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-  Inducible Chemokines

(2012) W. Peng et al.   CANCER RESEARCH

Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer

(2009) Bernhard Mlecnik et al.   GASTROENTEROLOGY

Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor

(2008) Inmaculada Rioja et al.   ARTHRITIS AND RHEUMATISM